Primary breast lymphoma.

abstract：:Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

journal_title：Leukemia & lymphoma

authors： Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

更新日期：2010-06-01 00:00:00

abstract：:A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

journal_title：Leukemia & lymphoma

authors： Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

更新日期：2012-02-01 00:00:00

abstract：:CD30 ligand (CD30L) is a type-II membrane glycoprotein capable of transducing signals through its specific counterstructure CD30. Even though there are indications that CD30L plays a key role as a paracrine-acting surface molecule in the deregulated cytokine cascade of Hodgkin's disease, little is known about its biol...

journal_title：Leukemia & lymphoma

authors： Gattei V,Degan M,Rossi FM,de Iuliis A,Mazzocco FT,Serraino D,Zagonel V,Aldinucci D,Pinto A

更新日期：1999-09-01 00:00:00

abstract：:To evaluate the prognostic impact of melphalan dose and total body irradiation (TBI) use in acute myeloid leukemia patients undergoing reduced-intensity allogeneic transplantation, we retrospectively compared outcomes of patients receiving a higher-dose (120-140 mg/m2, n = 379) or lower-dose melphalan (80-110 mg/m2, n...

journal_title：Leukemia & lymphoma

authors： Harada K,Yanada M,Machida S,Kanamori H,Onizuka M,Ozawa Y,Kobayashi H,Sawa M,Katayama Y,Ohashi K,Kanda J,Ichinohe T,Atsuta Y,Yano S

更新日期：2019-06-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:This study reports an autopsy case of a 53 year-old male with rapidly progressive extra-nodal NK/T-cell lymphoma accompanied with unusual clinical and pathologic features. He was initially presented with localized swelling and tenderness in the right lower extremity and the biopsy from the calf muscle was interpreted ...

journal_title：Leukemia & lymphoma

authors： Min HS,Hyun CL,Paik JH,Jeon YK,Choi G,Park SH,Seo JW,Kim CW

更新日期：2006-02-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been described as a possible prognostic marker in patients with acute myeloid leukemia (AML). However, the results in this field are not reproducible in different cohorts. In this study, we investigated WT1 mutations, expression levels and SNP rs1675...

journal_title：Leukemia & lymphoma

authors： Luo S,Yu K,Yan QX,Shen ZJ,Wu JB,Chen HM,Gao SM

更新日期：2014-02-01 00:00:00

abstract：:The distribution of subtypes of non-Hodgkin lymphoma (NHL) in Latin America is not well known. This Chilean study included 207 consecutive cases of NHL diagnosed at five cancer centers in the capital, Santiago, and one center in Viña del Mar. All cases were reviewed and classified independently by five expert hematopa...

journal_title：Leukemia & lymphoma

authors： Cabrera ME,Martinez V,Nathwani BN,Muller-Hermelink HK,Diebold J,Maclennan KA,Armitage J,Weisenburger DD

更新日期：2012-07-01 00:00:00

abstract：:Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly. The Philadelphia positive (Ph+) clone was however still...

journal_title：Leukemia & lymphoma

authors： Michaeli J,Fibach E,Rachmilewitz EA

更新日期：1993-10-01 00:00:00

abstract：:In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one pat...

journal_title：Leukemia & lymphoma

authors： Rodriguez V,Anderson PM,Litzow MR,Erlandson L,Trotz BA,Arndt CA,Khan SP,Wiseman GA

更新日期：2006-08-01 00:00:00

abstract：:The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

journal_title：Leukemia & lymphoma

authors： Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

更新日期：2016-11-01 00:00:00

abstract：:The purpose of this paper is to report the clinical characteristics and treatment outcome following different therapeutic approaches in a large series of patients with primary low-grade MALT lymphoma of the stomach. A total of ninety-three patients (median age 63 years) were reviewed. The patients were treated by diff...

journal_title：Leukemia & lymphoma

authors： Pinotti G,Zucca E,Roggero E,Pascarella A,Bertoni F,Savio A,Savio E,Capella C,Pedrinis E,Saletti P,Morandi E,Santandrea G,Cavalli F

更新日期：1997-08-01 00:00:00

abstract：:We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide...

journal_title：Leukemia & lymphoma

authors： Reiser M,Schnell R,Straub G,Borchmann P,Wilhelm M,Ubelacker R,Wörmann B,Münch R,Diehl V,Engert A

更新日期：1998-10-01 00:00:00

abstract：:To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

journal_title：Leukemia & lymphoma

authors： Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

更新日期：2014-06-01 00:00:00

abstract：:Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopaus...

journal_title：Leukemia & lymphoma

authors： Lhommé C,Brault P,Bourhis JH,Pautier P,Dohollou N,Dietrich PY,Akbar-Zadeh G,Lucas C,Pico JL,Hayat M

更新日期：2001-09-01 00:00:00

abstract：:Multiple myeloma (MM) is an essentially incurable malignancy associated with profound immune dysregulation. Despite the advent of novel therapies and improvements in survival over the last 10 years, death from progressive disease and infection remains a common outcome. Natural killer (NK) cells are CD56(+)CD3(-) large...

journal_title：Leukemia & lymphoma

authors： Godfrey J,Benson DM Jr

更新日期：2012-09-01 00:00:00

abstract：:The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

journal_title：Leukemia & lymphoma

authors： Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

更新日期：2002-06-01 00:00:00

abstract：:The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

journal_title：Leukemia & lymphoma

authors： Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

更新日期：2019-12-01 00:00:00

abstract：:We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy. Patients receiving DCAG had a similar overall response rate (ORR) (p = ...

journal_title：Leukemia & lymphoma

authors： Huang J,Hong M,Zhu Y,Zhao H,Zhang X,Wu Y,Lian Y,Zhao X,Li J,Qian S

更新日期：2018-11-01 00:00:00

abstract：:Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

journal_title：Leukemia & lymphoma

authors： Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

更新日期：2020-06-01 00:00:00

abstract：:Although the recognition of hybrid acute leukemia (HAL) is still controversial, several reports have described cytogenetic findings in these leukemias over the last 3 years. A distinct chromosomal profile appears to be associated with different immunologic subsets of HAL. The classical t(15;17), and inv(16) as well as...

journal_title：Leukemia & lymphoma

authors： Cuneo A,Boogaerts M,Ferrant A,Michaux JL,Bosly A,Louwagie A,Van den Berghe H,Balsamo R,Roberti G,Bardi A

更新日期：1995-01-01 00:00:00

abstract：:Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

journal_title：Leukemia & lymphoma

authors： Bröckelmann PJ,Borchmann P,Engert A

更新日期：2016-09-01 00:00:00

abstract：:A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

journal_title：Leukemia & lymphoma

authors： Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

更新日期：2004-03-01 00:00:00

abstract：:The relative scarcity of Hodgkin (H) and Reed-Sternberg (RS) cells within biopsies from cases with Hodgkin's disease (HD) is an impediment to the analysis of the nature and function of these cells. Continuous cell lines as uniform and permanently available sources of cells provide a valid alternative. Development of H...

journal_title：Leukemia & lymphoma

authors： Drexler HG

更新日期：1993-01-01 00:00:00

abstract：:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

journal_title：Leukemia & lymphoma

authors： Hawley RG,Berger LC

更新日期：1998-05-01 00:00:00

abstract：:There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

journal_title：Leukemia & lymphoma

authors： Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

更新日期：2011-05-01 00:00:00

abstract：:Hepatitis due to reactivation of hepatitis B virus is an important cause of liver-related morbidity and mortality in hepatitis B surface antigen (HBsAg) positive patients undergoing autologous hematopoeitic cell transplantation. With the recent introduction of sensitive serum HBV DNA quantitation assay, the diagnosis ...

journal_title：Leukemia & lymphoma

authors： Ma SY,Lau GK,Cheng VC,Liang R

更新日期：2003-08-01 00:00:00

abstract：:Data on quality of life (QOL) specifically in maintenance therapy of acute lymphoblastic leukemia (ALL) are minimal. This study was done to assess various items listed in domains of QOL (physical, emotional, social and school health domains) of children with ALL during maintenance therapy, and compare the same with th...

journal_title：Leukemia & lymphoma

authors： Bansal M,Sharma KK,Vatsa M,Bakhshi S

更新日期：2013-05-01 00:00:00

abstract：:Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

journal_title：Leukemia & lymphoma

authors： Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

更新日期：2021-01-11 00:00:00